Patent SG-11201806261X-A (SG)
Title: Bcma antibodies and use of same to treat cancer and immunological disorders
Inventor: SUSSMAN DJANGO
IPC: C07K16/30
Filed: 2017-02-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111010111111110110111011111011110111111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/143069 Al 24 August 2017 (24.08.2017) WI P0 I P CT (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 39/395 (2006.01) C07K 16/28 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 45/06 (2006.01) C07K 16/30 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/US2017/018177 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 16 February 2017 (16.02.2017) TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/296,594 17 February 2016 (17.02.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/396,084 16 September 2016 (16.09.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: SEATTLE GENETICS, INC. [US/US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 21823 30th Drive SE, Bothell, Washington 98021 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: SUSSMAN, Django; 21823 30th Drive SE, GW, KM, ML, MR, NE, SN, TD, TG). Bothell, Washington 98021 (US). RYAN, Maureen; Declarations under Rule 4.17: _ 21823 30th Drive SE, Bothell, Washington 98021 (US). — WESTENDORF, Lori; 21823 30th Drive SE, Bothell, as to applicant's entitlement to apply for and be granted a Washington 98021 (US). FELDHAUS, Michael; 21823 patent (Rule 4.1700) — — 30th Drive SE, Bothell, Washington 98021 (US). — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Agents: KELLY, Beth L. et al.; 21823 30th Drive SE, = (74) Bothell, Washington 98021 (US). Published: Designated States (unless otherwise indicated, for every — with international search report (Art. 21(3)) = (81) kind of national protection available): AE, AG, AL, AM, _ with sequence listing part of description (Rule 5.2(a)) = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, = = (54) Title: BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS = Fig. 23. In Vivo Activity of Single Dosed hSG16.17-SEA in NCI-H929-luciferase Disseminated _ _ === Tumor Model in NSG Mice. = °\" 1 A === = r VI* ..'.! a _ — Jr. .516.- = 140/i • V ogl _ OP 16 24 25 3G 35 4 1 - 1 it Dnyd -4, untrated 01 -- !, , ' ,(11 , A ollIz1) SE? (gab-4a - 1 0 -0- b.40::'_1\" •,1-Uls\".2 , TT ].'r , 1_ - .1, p . :-,;-gi C 4 \") 71- , .6.- h00•, -1..:i.'. , ::tirade 3ingXg 1-1 ado amoro sr3 IN 1-1 (57) : The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment 0 and diagnoses of various cancers and immune disorders as well as detecting BCMA. ei 0